万泰生物二价HPV疫苗通过WHO PQ周期性复核

Core Viewpoint - Wantai Biological's subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has received confirmation from the World Health Organization (WHO) regarding the prequalification of its bivalent human papillomavirus (HPV) vaccine, following its initial WHO PQ certification in 2021 [1] Group 1 - The bivalent HPV vaccine is a preventive biological product developed by Wantai Canghai, which received drug registration approval from the National Medical Products Administration on December 30, 2019 [1] - The vaccine was officially launched in mainland China (excluding Hong Kong, Macau, and Taiwan) in May 2020, targeting women aged 9 to 45 [1] - The vaccine is designed to prevent cervical cancer and related conditions caused by high-risk HPV types 16 and 18, including CIN2/3, adenocarcinoma in situ (AIS), and CIN1, as well as persistent infections caused by these HPV types [1]